SCHEMBL5408049

SCHEMBL5408049

CNc1nccn2c(-c3cccc(Cl)c3)cnc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.53
FLT3 P36888 7/20 0.52
MAP4K4 O95819 1/20 0.45
CYP17A1 P05093 1/20 0.43
BRAF P15056 1/20 0.42
IDO1 P14902 1/20 0.42
TTK P33981 3/20 0.41
DYRK3 O43781 1/20 0.41
CCNT1 O60563 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
DYRK1A Q13627 1/20 0.41
CDK5R1 Q15078 1/20 0.41
DYRK2 Q92630 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
FYN P06241 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411370 0.86 FLT3 (0.53) FLT3TTKFYN
SCHEMBL5420238 0.85 FLT3 (0.52) FLT3TTKCDK2FYNADORA3
SCHEMBL5401321 0.85 FLT3 (0.52) FLT3MAP4K4TTKDYRK3CCNT1
SCHEMBL5403440 0.84 FLT3 (0.59) FLT3MAP4K4TTKDYRK1ADYRK1B
SCHEMBL5413864 0.83 KDM4E (0.55) FLT3TTKKDM4EMEN1NPC1
SCHEMBL5411416 0.82 FLT3 (0.50) FLT3TTKFYN
SCHEMBL5418682 0.81 FLT3 (0.49) FLT3CYP17A1BRAFTTKDYRK3
SCHEMBL5404865 0.81 FLT3 (0.56) FLT3MAP4K4TTKDYRK1ADYRK1B
SCHEMBL5411929 0.81 IKBKB (0.49) FLT3BRAFTTK
SCHEMBL5396387 0.81 FYN (0.48) FLT3MAP4K4TTKDYRK1BFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 US claimed
US-20040220189-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors SUGEN, INC. 2004-11-04 US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 US disclosed
US-7157460-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157460-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 US disclosed
US-20040220189-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors SUGEN, INC. 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 BACE1 2815/4885FLT3 216/4885MAP4K4 24/4885
US-20040220189-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors MAP3K8, MAP4K4, MAP3K2 BACE1 4386/4885FLT3 215/4885MAP4K4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.